Login to Your Account



Panel backs FDA proposal to mandate gadolinium studies

By Mark McCarty
Regulatory Editor

Friday, September 8, 2017

Members of the FDA's Medical Imaging Drugs Advisory Committee were nearly universal in their view that the data are not sufficient to tie the use of gadolinium to adverse events in patients with normal renal function, but the panel unanimously backed the agency's proposal to require additional postmarket studies of those contrast agents.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription